小脑
溴尿嘧啶
化学
药物发现
蛋白质水解
生物化学
细胞生物学
药理学
泛素
泛素连接酶
生物
酶
DNA
组蛋白
基因
作者
Jaeki Min,Anand Mayasundari,Fatemeh Keramatnia,Barbara Jonchère,Seung Wook Yang,Jamie Jarusiewicz,Marisa Actis,Sourav Das,Brandon Michael Young,Jake Slavish,Lei Yang,Yong Li,Xiang Fu,Shalandus H. Garrett,Mi‐Kyung Yun,Zhenmei Li,Stanley Nithianantham,Sergio C. Chai,Taosheng Chen,Anang A. Shelat
标识
DOI:10.1002/ange.202108848
摘要
Abstract Targeting cereblon (CRBN) is currently one of the most frequently reported proteolysis‐targeting chimera (PROTAC) approaches, owing to favorable drug‐like properties of CRBN ligands, immunomodulatory imide drugs (IMiDs). However, IMiDs are known to be inherently unstable, readily undergoing hydrolysis in body fluids. Here we show that IMiDs and IMiD‐based PROTACs rapidly hydrolyze in commonly utilized cell media, which significantly affects their cell efficacy. We designed novel CRBN binders, phenyl glutarimide (PG) analogues, and showed that they retained affinity for CRBN with high ligand efficiency (LE >0.48) and displayed improved chemical stability. Our efforts led to the discovery of PG PROTAC 4 c (SJ995973), a uniquely potent degrader of bromodomain and extra‐terminal (BET) proteins that inhibited the viability of human acute myeloid leukemia MV4‐11 cells at low picomolar concentrations (IC50=3 pM; BRD4 DC50=0.87 nM). These findings strongly support the utility of PG derivatives in the design of CRBN‐directed PROTACs.
科研通智能强力驱动
Strongly Powered by AbleSci AI